Sleep Research Laboratory, St. Vincent's University Hospital, Dublin, Ireland.
J Clin Sleep Med. 2009 Oct 15;5(5):422-7.
Nasal side effects are common in patients with obstructive sleep apnea syndrome (OSAS) starting on nasal continuous positive airway pressure (CPAP) therapy. We tested the hypothesis that heated humidification or nasal topical steroids improve compliance, nasal side effects and quality of life in this patient group.
125 patients with the established diagnosis of OSAS (apnea/hypopnea index > or = 10/h), who tolerated CPAP via a nasal mask, and who had a successful CPAP titration were randomized to 4 weeks of dry CPAP, humidified CPAP or CPAP with additional topical nasal steroid application (fluticasone, GlaxoWellcome). Groups were similar in all demographic variables and in frequency of nasal symptoms at baseline. Outcome measures were objective compliance, quality of life (short form 36), subjective sleepiness (Epworth Sleepiness Scale score) and nasal symptoms such as runny, dry or blocked nose, sneezing and headaches; all variables assessed using a validated questionnaire and by direct interview.
There was no difference in compliance between groups after 4 weeks (dry: 5.21 +/- 1.66 h/night, fluticasone: 5.66 +/- 1.68, humidifier: 5.21 +/- 1.84; p = 0.444). Quality of life and subjective sleepiness improved in all groups, but there were no differences in the extent of improvement. Nasal Symptoms were less frequently reported in the humidifier group (28%) than in the remaining groups (dry: 70%, fluticasone: 53%, p = 0.002). However, the addition of fluticasone resulted in increased frequency of sneezing.
The addition of a humidifier, but not nasal steroids decreases the frequency of nasal symptoms in unselected OSAS patients initiating CPAP therapy; however compliance and quality of life remain unaltered.
患有阻塞性睡眠呼吸暂停综合征(OSAS)的患者在开始接受经鼻持续气道正压通气(CPAP)治疗时,常会出现鼻部副作用。我们假设加热湿化或鼻内局部类固醇能改善此类患者的顺应性、鼻部副作用和生活质量。
125 例确诊为 OSAS(呼吸暂停/低通气指数>或=10/小时)的患者,这些患者经鼻罩能耐受 CPAP 治疗,且 CPAP 滴定成功,他们被随机分配至 4 周的干燥 CPAP、湿化 CPAP 或 CPAP 加鼻内局部类固醇应用(氟替卡松,葛兰素威康)。各组在所有人口统计学变量和基线时的鼻部症状频率方面均相似。结果测量指标为客观顺应性、生活质量(36 项简短健康调查问卷)、主观嗜睡(嗜睡量表评分)和鼻部症状,如流涕、鼻干或鼻塞、打喷嚏和头痛;所有变量均使用经证实的问卷和直接访谈进行评估。
4 周后各组间的顺应性无差异(干燥:5.21±1.66 小时/夜;氟替卡松:5.66±1.68;湿化器:5.21±1.84;p=0.444)。所有组的生活质量和主观嗜睡均改善,但改善的程度无差异。湿化器组的鼻部症状报告频率较低(28%),明显低于其余组(干燥:70%;氟替卡松:53%;p=0.002)。然而,氟替卡松的应用导致打喷嚏的频率增加。
在未选择的开始 CPAP 治疗的 OSAS 患者中,应用湿化器而非鼻内类固醇可降低鼻部症状的发生频率,但顺应性和生活质量未改变。